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Outcome of Patients With Hypertrophic
Cardiomyopathy and a Normal Electrocardiogram
Christopher J. McLeod, MB, CHB, PHD, Michael J. Ackerman, MD, PHD, Rick A. Nishimura, MD,
A. Jamil Tajik, MD, Bernard J. Gersh, MB, CHB, DPHIL, Steve R. Ommen, MD
Rochester, Minnesota
Objectives This study sought to clarify the frequency, clinical phenotype, and prognosis of those patients with hypertrophic
cardiomyopathy (HCM) who present with a normal electrocardiogram (ECG).
Background Hypertrophic cardiomyopathy is the most common cause of sudden death in young people. Screening advocates
have recommended a 12-lead ECG for the early detection of HCM in athletes, yet the clinical outcomes of those
presenting with a normal ECG remains to be fully delineated.
Methods Baseline characteristic and echocardiographic data were collected on all patients with HCM who initially pre-
sented to our institution with a diagnostic echocardiogram but a normal ECG. Follow-up was obtained and com-
pared with the prognosis of HCM patients who presented with abnormal ECGs.
Results We compared 135 HCM patients with a normal ECG with 2,350 HCM patients with an abnormal ECG. The latter
group was more likely to have worse symptoms, have higher gradients, and a greater degree of septal wall
thickness than the patients with a normal ECG. Severe obstructive symptoms requiring surgical myectomy and
implantation of an implantable cardioverter-defibrillator were more common in patients with abnormal ECGs.
Cardiac survival was significantly better in the group with a normal ECG at presentation—none of these patients
had a cardiac death at follow-up.
Conclusions Almost 6% of patients presenting with demonstrable echocardiographic evidence of HCM had a normal ECG at
the time of diagnosis. This subset of patients with normal ECG-HCM appears to exhibit a less severe phenotype
with better cardiovascular outcomes. (J Am Coll Cardiol 2009;54:229–33) © 2009 by the American College of
Cardiology Foundation
ublished by Elsevier Inc. doi:10.1016/j.jacc.2009.02.071f
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pypertrophic cardiomyopathy (HCM) is a disease of the
arcomere characterized by left ventricular hypertrophy. The
attern of hypertrophy is typically asymmetric affecting
redominantly the ventricular septum, yet some patients
xhibit a disproportionate involvement of the apex or free
all. The electrocardiogram (ECG) is abnormal in most
atients with HCM, with electrocardiographic criteria for
eft ventricular hypertrophy and widespread Q waves (1).
ariants such as apical HCM may show a distinctive pattern
f diffuse symmetric T-wave inversions across the precor-
ium (2–4). The ECG is often used as a principle screening
ool for HCM, particularly in large otherwise healthy
opulations and pre-participation athletic screening pro-
rams (5–8). The purpose of this study was to examine how
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009, accepted February 23, 2009.requently patients with echocardiographically documented
CM present with a completely normal ECG and to
haracterize the phenotype and outcomes of patients with a
ormal ECG-HCM.
ethods
his study was approved by the Mayo Clinic Institutional
eview Board. All patients with the diagnosis of HCM and
ormal 12-lead ECG at the Mayo Clinic, Rochester, in the
eriod from April 1, 1994, to October 30, 2006, were
dentified. During this period, 2,485 patients with a diag-
osis of HCM were seen. Of those, 135 patients were
dentified as having a normal ECG, and the remaining
,350 patients exhibited an abnormal ECG. The diagnosis
f HCM was based on the presence of a hypertrophied,
ondilated left ventricle in the absence of other diseases
apable of producing the degree of observed hypertrophy.
he primary imaging modality used for diagnosis in all
atients was transthoracic 2-dimensional and Doppler
chocardiography. Patients found to have outflow tract
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tinely underwent Valsalva ma-
neuvers. If this provocation did not
raise the gradient significantly,
then amyl nitrite inhalation was
performed in our echocardio-
graphic evaluation. Exercise test-
ng or invasive assessment was obtained in select cases at the
iscretion of the clinician if the echocardiogram demonstrated
o resting or latent obstruction.
Patients with potential confounding coexisting disease(s)
ere excluded from this analysis, by definition, as were
atients with other causes for left ventricular hypertrophy.
ollow-up obtained via clinic visit, mailed questionnaire,
elephone survey, and Social Security Death Index search
as 100% complete for the patients with a normal ECG at
.6  6.0 years with respect to mortality.
The HCM-related mortality included sudden cardiac
eath (unexpected within 1 h of a witnessed collapse or
octurnal), heart failure death (in the context of progressive
ardiac decompensation), and stroke-related death (9). Ap-
ropriate discharges from implantable defibrillators for ven-
ricular fibrillation or sustained ventricular tachycardia were
egarded as sudden deaths. Invasive septal therapy was
ffered to patients with significant outflow tract obstruction
ho remained symptomatic despite appropriate pharmaco-
ogic therapy (10,11). The choice of pursuing implantable
ardioverter-defibrillator insertion was made on an individ-
al patient basis, taking into consideration the presence of 1
r more risk factors for sudden cardiac death (12), following
comprehensive discussion of the risks and benefits of this
articular risk management strategy. No patients, however,
ad undergone septal myectomy or septal ablative therapy
efore the initial visit ECGs. Coronary artery disease was
xcluded by history of prior infarction or intervention, or the
resence of symptoms. Patients with cardiovascular risk
actors or over 40 years old routinely underwent coronary
ngiography before septal reduction surgery.
For our analysis, patients with a first- or second-degree
elative confirmed to have the diagnosis of HCM were
lassified as having a positive family history of the disease.
lectrocardiographic measurements. The 12-lead ECGs
or each of the eligible patients were obtained from the
ayo Clinic Electrocardiography Database. This database
rovides electronic copies of all electrocardiographic trac-
ngs and includes detailed, prospectively defined and vali-
ated computerized interpretations that are over-read and
onfirmed by technicians and cardiologists. The reference
CG used was a standard 12-lead that was obtained in all
tudy subjects at the time of the initial evaluation for HCM
t the Mayo Clinic. An ECG was diagnosed as “normal” on
he basis of criteria that were outlined in the initial descrip-
ion of ECG abnormalities in HCM by Savage et al. (13)
nd were again individually reviewed by 1 author (C.J.M.).
t is important to note that these criteria do encompass the
Abbreviations
and Acronyms
ECG  electrocardiogram
HCM  hypertrophic
cardiomyopathyefinitions set by the European Society of Cardiology (7) tnd Italian pre-participation screening programs (14). Es-
entially, the normal ECG group presented no evidence of
ate abnormality, P- or QRS-axis deviation, abnormal
oltage for age and sex, criteria for left or right atrial
nlargement, ST- or T-wave changes (15), P-R (200 ms)
r QRS prolongation (120 ms), or abnormal Q waves
15). One ECG was reclassified during the over-read process
s abnormal, based on Cornell, Scott, and Estes criteria, after
n initial normal computer-based classification.
tatistical methods. Data are presented as mean  SD for
ontinuous data and as number and percentage for categorical
ata. A p value 0.05 was considered significant in all
tatistical analyses. Pearson likelihood ratio tests were used in
he contingency analysis—and these are displayed in the
ables—and the t test was used in the 1-way analyses. Survival
nalysis testing between groups was compared using log-rank
esting, and the Kaplan-Meier survival curves were constructed
sing the product-limit method.
esults
atients with HCM and a normal ECG. A total of 135
atients (6% of total eligible HCM patients) were identified
s having a normal ECG. There were 57 (42%) men and 78
58%) women; the mean  SD age was 55  18 years
range 8.4 to 91.5 years). Fourteen patients (10.4% of those
ith a normal ECG and1% of all studied HCM patients)
ere individuals under the age of 30 years. In the group of
atients who were under the age of 30 years and presenting
ith a normal ECG, 11 (78.6%) of 14 had a family history
f HCM. In the remaining 3 patients, the diagnostic
nvestigation with echocardiography was pursued by the
hysician because of a murmur (n  2) or poor effort
olerance (n  1). Clinical and echocardiographic charac-
eristics of the group are shown in Table 1. The septal
hickness averaged 17.3  4 mm, and the mean resting
radient was 29.1  33 mm Hg (range 0 to 154 mm Hg).
Forty-seven (34.8%) patients presented with a history of
re-syncope, and 11 (8.1%) gave a history of syncope. In
ddition, a large proportion of the patients were asymptomatic
rom a New York Heart Association functional classification
tandpoint: 97 (71.9%) were free from anginal symptoms, and
1 (45.2%) were free from dyspnea. Only 2 patients had angina
t rest, and a single patient had dyspnea at rest—class IV
ymptoms. Six patients (4.3%) had a background of a prior
troke. Furthermore, 66 patients (46.8%) were mildly hyper-
ensive and 11 (7.8%) were diabetic.
The most commonly used cardiac medications were beta-
drenergic blockers (43.7%), calcium-channel antagonists
25.2%), disopyramide (1.5%), and amiodarone (n  1).
Follow-up of this group (after an average of 5.7  6
ears) revealed that 30 (22.2%) patients were subsequently
eferred for septal myectomy to relieve obstructive symp-
oms refractory to pharmacotherapy, and 6 (4.4%) under-
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July 14, 2009:229–33 Patients With HCM and a Normal ECGent septal ablation. Based on perceived increase in risk
f sudden cardiac arrest, 4 (3.0%) patients were referred
or placement of an implantable defibrillator device for
rimary prevention only. Atrial fibrillation developed in
1 patients (8.1%). There were no documented episodes
f sudden cardiac death or appropriate implantable
ardioverter-defibrillator discharges in the follow-up of
his group. A total of 58 patients (43%) had a subsequent
CG performed at least 2 months after the initial ECG.
mong these patients, 30 (52%) remained normal at a
ean follow-up time of 6.0  4.1 years. The remaining
8 (48%) had developed a detectable ECG abnormality.
An increased body surface area may attenuate the increased
CG voltage found in hypertrophy. Patients presenting with a
ormal ECG but a body surface area 2.4 m2 were identified
n 7), and there were no differences in clinical characteristics
aseline CharacteristicsTable 1 Baseline Characteristics
Normal ECG
(n  135)
Abnormal ECG
(n  2,350) p Value
Age, yrs 55 18 47 21 0.001
Patients 30 yrs 14 (10.4) 453 (19.3) 0.001
Males 57 (42.2) 1,318 (56.1) 0.0002
Myectomy 30 (22.2) 790 (33.6) 0.002
Ablation 6 (4.4) 145 (6.2) 0.37
ICD 4 (3.0) 315 (13.4) 0.0003
Angina 0.18
1 94 (69.6) 1,211 (57.8)
2 31 (23.0) 532 (25.4)
3 8 (5.9) 289 (13.8)
4 2 (1.5) 33 (1.6)
Dyspnea (NYHA functional class) 0.04
1 58 (43.0) 748 (33.7)
2 34 (25.2) 510 (23.0)
3 42 (31.1) 890 (40.1)
4 1 (0.7) 68 (3.1)
Family history of HCM 28 (20.7) 572 (24.3) 0.15
Pre-syncope 47 (34.8) 852 (40.4) 0.21
Syncope 11 (8.1) 263 (12.1) 0.12
Sudden cardiac arrest 0 (0.0) 14 (1.3) 0.82
Atrial fibrillation (paroxysmal) 10 (7.4) 374 (17.6) 0.007
Atrial fibrillation (chronic) 1 (0.7) 50 (4.4) 0.08
Stroke 6 (4.4) 102 (4.8) 0.95
Diabetes mellitus 11 (8.1) 98 (4.7) 0.09
Hypertension 66 (48.9) 668 (31.5) 0.001
Beta-blocker 59 (43.7) 1,301 (70.0) 0.0001
Calcium blocker 34 (25.2) 729 (41.2) 0.01
Disopyramide 2 (1.5) 161 (8.3) 0.01
Amiodarone 1 (0.7) 116 (5.9) 0.02
Warfarin 3 (2.2) 238 (12.2) 0.001
Resting gradient, mm Hg 29.1 33 42.4 43 0.001
Septal wall thickness, mm 17.3 4 19.8 6 0.001
Clinical follow-up 5.7 6 4.5 5
alues are mean  SD or n (%).
ECG  electrocardiogram; HCM  hypertrophic cardiomyopathy; ICD  implantable
ardioverter-defibrillator; NYHA  New York Heart Association.r outcomes in this group. aomparison with HCM patients with an abnormal
CG. The normal ECG group was compared subse-
uently with patients from our HCM database who initially
resented with an abnormal ECG (Table 1). The abnormal
CG group was composed of younger patients with more of
male preponderance, and an overall higher New York
eart Association dyspnea class. There was no significant
ifference in the frequency of a background of family history
f the disease. They were also more likely to undergo septal
yectomy surgery at a later date for severe intractable
ymptoms. There was a higher resting gradient and septal
all thickness in this abnormal ECG group. Interestingly,
he finding of hypertension was far more common in the
atients presenting with a normal ECG (48.9% vs. 28%,
 0.001).
urvival analysis. Overall survival of the normal ECG
roup at 5 and 10 years was 92% and 81%, respectively, and
as not different from age- and sex-matched controls from
he general population (chi-square: 0.18) (Fig. 1A). Com-
arison with the abnormal ECG-HCM group, however,
evealed improved cardiac survival in the normal ECG
roup, as there were no cardiac deaths noted in this group
Fig. 1B) (chi-square: 0.04).
iscussion
he 12-lead ECG is a fundamental initial diagnostic
odality for the early evaluation of a patient suspected of
aving HCM; at times, it is the only sign of the disease
n an otherwise asymptomatic individual (16). In prior
nvestigations (17–19) of patients with mutations in
ardiac myofilaments, ECG had a similar accuracy (sen-
itivity: 60%, specificity: 98%) in the diagnosis of
CM as echocardiography (left ventricular wall thick-
ess: 13 mm).
The principle findings of the current study are: 1) that a
ormal ECG can be observed in 5% to 10% of patients with
chocardiographic evidence of HCM; and 2) that patients
ith HCM and a normal ECG have less severe phenotypic
xpression of HCM as evidenced by lower wall thickness,
eft ventricular outflow tract gradient, symptom progression,
omplication rates, and cardiac-related mortality as com-
ared with HCM patients with abnormal ECGs.
Interestingly, ECG has been recommended as the initial
creening tool in large healthy populations and pre-
articipation athletic programs. However, there is a subset
f patients with the phenotypic expression of the disease by
chocardiography that does not have an abnormal ECG. It
s thus necessary to understand the frequency, clinical
haracteristics, and prognosis of this group.
In our study, a normal ECG was found in 6% of a large,
iverse population of patients with documented HCM,
hich remains in concordance with previous literature
1,13). Compared with HCM patients with an abnormal
CG, those with a normal ECG presented at an older agend with less severe disease expression. This was character-
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Patients With HCM and a Normal ECG July 14, 2009:229–33zed clinically by fewer dyspneic symptoms, less myocardial
ypertrophy, and a lower gradient at echocardiography. A
ormal ECG appears to predict a more benign course with a
educed need for myectomy or an implantable cardioverter-
efibrillator, and no patient had sudden cardiac death at
ntermediate term follow-up. Similarly, extensive experience
ith ECG screening in Italy has suggested that the identifi-
ation of athletes without significant repolarization abnormal-
ties (representing 95% of athletes screened) appears to predict
very low risk of subsequent cardiovascular disease or compli-
ations thereof (8).
These findings will be of interest to the ongoing inter-
ational discussions on the appropriate screening for HCM
mong the general population and competitive athletes
20–24). Although sudden death in young competitive
thletes may be due to a variety of cardiovascular diseases,
5302 3015 525 10
Time (years)
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
O
ve
ra
ll 
su
rv
iv
al
Abnormal ECG
Normal ECG
Expected
20 353015 525 10
0.1
0.2
0.3
0.4
0.5
0.6
0.7
0.8
0.9
1.0
Su
rv
iv
al
 fr
ee
 fr
om
 c
ar
di
ac
 d
ea
th
Time (years)
Normal ECG
Abnormal ECG
*
A
B
Figure 1 Clinical Outcomes
No difference in overall survival was found between the 2 patient groups—
stratified according to a normal or abnormal ECG (chi-square: 0.27)—compar-
ing similarly with age- and sex-matched controls (chi-square: 0.18) (A). Cardiac
survival, however, was found to be more disparate with no cardiac deaths iden-
tified in the normal ECG group (chi-square: 0.04) (B). *p  0.04. ECG 
electrocardiogram.he most common single disease entity in North America isCM, which occurs in up to one-third of all sudden deaths
uring athletics (25,26).
Importantly, although only 1 ECG was over-read as abnor-
al after the initial normal computer-based classification, this
isclassified patient subsequently sustained a sudden cardiac
eath at 41 years of age during exercise, underscoring the
mportance that physicians not rely solely on the computer-
ased algorithms for diagnosis and screening.
The 6% incidence of normal ECGs among HCM pa-
ients needs to be considered from the other viewpoint.
iven that HCM has an overall prevalence of 0.2% in the
eneral screening population and that only 6% of those
CM patients will have a normal ECG, in any general
creening, there may be 1 normal ECG-HCM patient for
very 10,000 patients screened.
tudy limitations. The study is limited by its retrospective
ature with a relatively restricted length of follow-up.
urthermore, in lieu of the relatively small sample size and
he well-recognized heterogeneity of clinical course in
CM, the absence of cardiac death is not guaranteed by a
ormal ECG, but rather our data, taken together with the
talian experience, suggest that patients with a normal ECG
ay have a better cardiac prognosis.
In light of the vast differences in cardiovascular hemody-
amics and electrophysiology with exercise and training,
hese outcomes may not be applicable to the subgroup of
ighly trained athletes. In addition, no analysis of gene muta-
ion status was performed to offer further insight into
enotype-phenotype relationships. Interestingly, as this com-
lex relationship continues to be characterized by newer
ophisticated techniques and a heterogeneous entity emerges—
nitially thought to be hallmarked by increased left ventricular
ass (27)—the basic ECG appears to remain a vital screening
ool.
onclusions
lmost 6% of patients presenting with demonstrable echo-
ardiographic evidence of HCM had a normal ECG at the
ime of diagnosis. This subset of patients with a normal
CG-HCM appears to exhibit a less severe phenotype with
etter cardiovascular outcomes.
eprint requests and correspondence: Dr. Steve R. Ommen,
ayo Clinic, 200 First Street SW, Rochester, Minnesota 55905.
-mail: ommen.steve@mayo.edu.
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